271 related articles for article (PubMed ID: 34168433)
1. The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.
Li J; Guo C; Wu J
Drug Des Devel Ther; 2021; 15():2619-2628. PubMed ID: 34168433
[TBL] [Abstract][Full Text] [Related]
2. Hepatic PPARs: their role in liver physiology, fibrosis and treatment.
Zardi EM; Navarini L; Sambataro G; Piccinni P; Sambataro FM; Spina C; Dobrina A
Curr Med Chem; 2013; 20(27):3370-96. PubMed ID: 23746272
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis.
Han X; Wu Y; Yang Q; Cao G
Pharmacol Ther; 2021 Jun; 222():107791. PubMed ID: 33321113
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Latruffe N; Vamecq J
Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
Strakova N; Ehrmann J; Bartos J; Malikova J; Dolezel J; Kolar Z
Neoplasma; 2005; 52(2):126-36. PubMed ID: 15800711
[TBL] [Abstract][Full Text] [Related]
6. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Thiemermann C
Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
[TBL] [Abstract][Full Text] [Related]
7. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
8. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
Deng YL; Xiong XZ; Cheng NS
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
10. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
Scatena R; Martorana GE; Bottoni P; Giardina B
IUBMB Life; 2004 Aug; 56(8):477-82. PubMed ID: 15545227
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
Da Silva Morais A; Abarca-Quinones J; Horsmans Y; Stärkel P; Leclercq IA
Int J Mol Med; 2007 Jan; 19(1):105-12. PubMed ID: 17143554
[TBL] [Abstract][Full Text] [Related]
12. PPAR: a mediator of peroxisome proliferator action.
Green S
Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
[TBL] [Abstract][Full Text] [Related]
13. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
Guan Y
Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
[TBL] [Abstract][Full Text] [Related]
14. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).
Staels B; Schoonjans K; Fruchart JC; Auwerx J
Biochimie; 1997; 79(2-3):95-9. PubMed ID: 9209702
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
[TBL] [Abstract][Full Text] [Related]
16. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Derosa G; Sahebkar A; Maffioli P
J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
[TBL] [Abstract][Full Text] [Related]
17. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors increase human sebum production.
Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
[TBL] [Abstract][Full Text] [Related]
19. Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.
Basilotta R; Lanza M; Casili G; Chisari G; Munao S; Colarossi L; Cucinotta L; Campolo M; Esposito E; Paterniti I
Cells; 2022 Feb; 11(4):. PubMed ID: 35203272
[TBL] [Abstract][Full Text] [Related]
20. Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis.
Wang HY; Cheng ML
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):179-84. PubMed ID: 18397855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
